Positive Phase 2b results in 2nd line melanoma
Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC
Breakthrough cancer treatment shows best-in-class potential to open up 2nd-line immunotherapy market to anti-PD1 resistant patients
- BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD-1 treatment
- Primary endpoint met with a 27% Overall Response Rate (ORR), 8% Complete Responses (CR) & 65% Disease Control Rate (DCR) substantially exceeding current standard of care; further improvements anticipated over one year follow up
- Hard-to-treat mucosal melanoma patients achieved 66% ORR and 100% DCR
- Durable responses and manageable safety profile, with no patients discontinuing due to adverse events
- Preparation for pivotal trial based on FDA guidance underway; potential for use in multiple solid cancers resistant to anti-PD1 inhibitors, and with different anti-PD1 combinations
MADRID, Spain, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced positive preliminary results of a Phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma whose disease had progressed on first-line anti-PD1-based therapy. BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.
Initial results of the study were presented today (12th November) in a late-breaking session at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington DC, Nov. 10-14, 2021. (LBA Poster Abstract (961): Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy, presented in the Poster Hall in Washington, D.C. and the virtual ePoster Hall beginning Friday, Nov. 12 at 7 a.m. EST).
"These are potentially game-changing results showing that BO-112 can rescue melanoma patients who have failed first-line immune-therapy with anti-PD1," saidDrCarlos Paya, Executive Chairman of Highlight Therapeutics. "Anti-PD1 basedimmunotherapy has revolutionized oncology treatments, but only a fraction of patients initially respond and many of these patients progress thereafter. These initial Phase 2 results show that BO-112 combined with a leading PD1 inhibitor rescue around 65% of anti-PD1 failing patients, making many of them respond to the combined treatment. These much-anticipated outcomes demonstrate BO-112's potential as a best-in-class therapy for melanoma patients whose disease has progressed on prior anti-PD1 treatment, and we now look forward to further clinical studies, not only in melanoma but in other major tumor types in which anti-PD1 resistance is also an issue."
Anti-PD1 therapies are valued at approximately $24 billion1 and are used across most solid tumors but currently fewer than 20% of all cancer patients benefit from first-line anti-PD1 treatment. BO-112 in combination with anti-PD1 therapy is designed to resensitize tumors to anti-PD1 treatment through improved antigen presentation, enhanced T-cell infiltration and increased MHC-1 and PDL1 expression by the tumor itself.
"This initial data is very encouraging and has the potential to change medical practice," said Dr. Marisol Quintero, CEO of Highlight Therapeutics. "The preliminary ORR of 27%, including 8% Complete Responses, already exceeds current standard of care, such as the use of anti-CTLA-4. Based on the mode of action and experience from previous BO-112 Phase 1 studies, additional follow-up of these patients is expected to deliver further improvements in ORR. We are also encouraged by the excellent safety profile, with no patients discontinuing the study due to adverse events. Highlight Therapeutics is in the planning stage of a pivotal Phase 3 trial, due to begin in 2022, and we look forward to opening discussions with potential partners to explorecombinations with anti-PD1s."
Highlight Therapeutics and Merck, known as MSD outside the United States and Canada, conducted an open-label, single arm study to evaluate the efficacy & safety of intra-tumoral administration of BO-112 + pembrolizumab in mucosal, acral and cutaneous melanoma patients whose disease had progressed, confirmed by two consecutive CT scans. The study recruited 42 patients in France and Spain, with recruitment completed by August 24, 2021. Patients included those with high LDH levels, which are often associated with poor response rates and have been excluded from comparable clinical trials.
The preliminary analysis shows:
- Primary endpoint (ORR by independent reviewer) has been met
- With a median follow up of three months, there is a clear clinical benefit in patients with confirmed anti-PD1-resistant melanoma, with a 27% ORR and a 65% DCR, superior to 2nd line Standard of Care in stage III/IV melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).
- Three hard-to-treat mucosal melanoma patients have achieved an ORR of 66% and DCR of 100%
- High baseline LDH levels (>3xULN) predict progressive disease
- Responses and SD are durable
- Study treatment has a manageable safety profile, with no patients discontinuing due to adverse events
Next steps in the development of BO-112 include:
- Initiation of a pivotal Phase 3 study in 2nd-line melanoma is planned in 2022 following discussions with regulatory agencies in the US and Europe
- Highlight Therapeutics has initiated strategic partnerships discussions with anti-PD1 companies interested in enhancing their anti-PD1 market potential
- Initial data from a sponsor-initiated Phase 1B trial by UCLA evaluating BO-112 + pembrolizumab in anti-PD1 resistant hepatocellular carcinoma currently recruiting patients is expected in 2022
1. IQVIA Global Oncology Report 2020
For more information, please contact:
|Highlight Therapeutics S. L.||email@example.com|
|Marisol Quintero, CEO|
|Mo PR Advisory||Tel: +44 (0) 7876 444977 / 07860 361746|
|Mo Noonan/Jonathan Birt|
|Consilium Strategic Communications||Tel: +44 7921 697654|
Notes to editors
About Highlight Therapeutics
Highlight Therapeutics, formerly known as Bioncotech Therapeutics, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn 'cold' tumors 'hot' and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy, a very large market opportunity. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.
For more information, please visit www.highlighttherapeutics.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EPH European Property Holdings Limited (EPH) announces Third Quarter 2021 Financial Update30.11.2021 19:00:00 CET | Press release
30November 2021, Road Town, Tortola, BVI I Ad hoc announcement pursuant to Art. 53 LR In Q3 2021, there were no significant changes in the Company’s financial position and/or structure of its balance sheet in comparison to the published semi-annual report, given that fair value of investment properties was not revaluated as of 30 September 2021. In Q3 2021, the Company demonstrated stable performance compared to the last year. The rental properties continued generating sufficient cash to cover the Company’s operating expenses, service the debt and partially finance its investment program. The net rental income (NRI) increased from US$45.33 mln in the first 9 months of 2020 to US$ 49.38 mln for 9 months of 2021. Thereof, European properties acquired during 2020 generated a total NRI of US$ 7.48 mln (9 months of 2020: US$ 2.67 mln). The performance of the other European properties, as well as Russian properties remained almost unchanged as compared to the same period of 2020.During Q3 20
NEXTENSA NV/SA: SHARES – VOTING RIGHTS AND DENOMINATOR PUBLICATION IN COMPLIANCE WITH ART. 15 OF THE LAW OF 2 MAY 2007 (THE TRANSPARENCY ACT)30.11.2021 17:40:00 CET | Press release
NEXTENSA NV/SA: SHARES – VOTING RIGHTS AND DENOMINATOR PUBLICATION IN COMPLIANCE WITH ART. 15 OF THE LAW OF 2 MAY 2007 (THE TRANSPARENCY ACT) As previously announced1, the EGM of 19 July 2021 introduced the double voting right (loyalty voting right), in accordance with article 7:53 of the Code of Companies and Associations. This means, in accordance with article 28 of the articles of association, that double voting rights are granted to each fully paid-up share that has been continuously registered in the share register in the name of the same shareholder for at least two years. The other shares give right to one vote. The two-year period starts from the date of registration of the nominative shares in the share register. In compliance with article 15 of the aforementioned Transparency Act, every month the Company must publish, on its website and by means of a press release, the total capital, the changes to the total number of voting securities and the total number of voting rights, i
Change in the number of shares and votes in Sinch AB (publ)30.11.2021 17:35:00 CET | Press release
Stockholm, Sweden – November 30, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that the number of shares and votes in Sinch AB (publ), registration number 556882-8908 (“Sinch”), amounts to 747,480,901 on November 30, 2021. The change in the number of shares and votes in November is a result of the issue of totally 1,317,537 new shares in connection with the closing of the acquisitions of MessageMedia and MessengerPeople, as previously communicated. For further information, please contact Ola Elmeland Investor Relations Director Mobile: +46 721 43 34 59 E-mail: email@example.com Thomas Heath Chief Strategy Officer & Head of Investor Relations Mobile: +46 722 45 50 55 E-mail: firstname.lastname@example.org About Sinch Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile m
Ändring av antalet aktier och röster i Sinch AB (publ)30.11.2021 17:35:00 CET | Pressemelding
Stockholm, Sverige – 30 november 2021 – Sinch AB (publ), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelade idag att antalet aktier och röster i Sinch AB (publ), org.nr 556882–8908 (”Sinch”), uppgår till 747 480 901 den 30 november 2021. Förändringen av antal aktier och röster under november har föranletts av att totalt 1 317 537 nya aktier har emitterats i samband med slutförandet av förvärven av MessageMedia och MessengerPeople, som tidigare har kommunicerats. För mer information, vänligen kontakta Ola Elmeland Investor Relations Director Mobile: +46 721 43 34 59 E-mail: email@example.com Thomas Heath Chief Strategy Officer & Head of Investor Relations Mobile: +46 722 45 50 55 E-mail: firstname.lastname@example.org Om Sinch Sinch utvecklar digitala verktyg som möjliggör en personlig interaktion mellan företag och individer. Med Sinch molnbaserade kommunikationsplattform kan företag nå världens alla mobiltelefoner – inom en eller ett par sekunder – via medd
GivingTuesday: NOVA Chemicals Expands Total COVID-19 Relief to US$1.25M with Additional Gifts30.11.2021 16:40:00 CET | Press release
Programs supporting mental health, food security, and overall community resiliency receive funding through corporate giving campaign Calgary, Alberta, Canada , Nov. 30, 2021 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5 www.novachemicals.com | 403.750.3600 tel | 403.269.7410 fax NOVA Chemicals Corporation (“NOVA Chemicals”) today announced an additional US$600,000 commitment in COVID-19-related supports across our operational regions, bringing the total amount given for pandemic relief to US$1.25M, as part of efforts to meaningfully give back to our neighbors and their communities. “While we continue to see positive momentum toward a world with higher vaccination rates and fewer restrictions, the impacts felt by the pandemic will unfortunately have lasting effects,” said Mona Jasinski, SVP HR and Communications, NOVA Chemicals. “I am proud of NOVA’s commitment to ensuring there is food on the table for tens of thousands of pe
KICKS CHOSES WESTPAY AS PROVIDER OF PAYMENT SOLUTIONS30.11.2021 16:40:00 CET | Press release
Westpay has today signed an agreement with Kicks regarding payment solutions in Sweden, Norway, and Finland. The solution enables card payments as well as Swish, Vipps, Mobile Pay, and other alternative payment methods. The value of the initial order amounts close to SEK 4 million during the coming three years. - Kicks is a solid and well-known brand in the Nordics. The customer experience is a key element in their success. Westpay and our solutions enable all the features and solutions they need to level up their overall offering. They made an accurate and relevant assessment and knew that their payment solution was required to support them in their ongoing business today as well as tomorrow. Now, they have a future-proof solution that they can rely on in their future journey, says Hans Edin, CCO at Westpay. KICKS is the Nordic region's leading beauty chain and offers a holistic concept in makeup, fragrance, skin care and hair care. With experts in 250 stores in Sweden, Norway and Fin
3-month sales of AB Linas Agro Group went up 84%, net profit was 199% higher30.11.2021 15:15:00 CET | Press release
During the three months of the financial year, the subsidiaries of AB Linas Agro Group, an owner of agricultural and food industry companies, sold 1.03 million tons of production or 34% more than in the previous year. Consolidated revenue of the Group grew by 84% and amounted to EUR 440 million. Consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 157% to EUR 24 million. The group of companies earned EUR 14 million operating profit or 193% more than in the previous year. Gross profit was EUR 38 million or 185% higher than during the last year. Profit before taxes grew by 187% to EUR 13 million. Net profit increased by 199% to EUR 12 million. “After acquiring the companies operating under KG Group brand, we expanded our operations in four segments, however the growth in some areas was determined not only by the acquisition, but also by the joint efforts of the team and synergies,” commented Mažvydas Šileika, Chief Financial Officer of AB Lin